# Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

> **NCT01004172** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 38 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Breast Cancer
- Progressive Breast Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** bevacizumab
- **DRUG:** herceptin

## Key facts

- **NCT ID:** NCT01004172
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-12
- **Final completion:** 2017-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-12-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004172, "Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01004172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*